Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthetic or recombinant fucosylated oligosaccarides for use in the treatment of infections

A technology of fucosylation and oligosaccharides, applied in the direction of organic active ingredients, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve the problem of not providing vaccines or compositions

Active Publication Date: 2015-10-28
CHR HANSEN HMO GMBH
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] In spite of the above background, different methods of treating or preventing norovirus infection currently exist, but there is still no provision of an actual vaccine or composition which has proven effective in such treatment / prevention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthetic or recombinant fucosylated oligosaccarides for use in the treatment of infections
  • Synthetic or recombinant fucosylated oligosaccarides for use in the treatment of infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0045] figure 1 Six kinds of oligosaccharides used as an example for the treatment or prevention of Norovirus and / or Rotavirus infection are shown, wherein Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc is shown in A, and B is shown GlcNAcα1-3(Fucα1-2)Galβ1-3GlcNAcβ1-3Galβ1-4Glc, Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc are shown in C, Galβ1-3(Fucα1-2 ) Galβ1-3GlcNAcβ1-3Galβ1-4Glc, Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4Glc are shown in E, and Fucα1-2Galβ1-4GalNAcβ1-3Galβ1-4Glc are shown in F. In the formula, Gal represents a galactose monosaccharide unit, Glc represents a glucose monosaccharide unit, GalNAc represents an N-acylated galactosamine monosaccharide unit and GlcNAc represents a glucosamine monosaccharide unit.

[0046] for in figure 1 The oligosaccharide shown in A, schematically outlines the glycosidic linkages between the monosaccharide units of the oligosaccharide of the invention: in figure 1 In the oligosaccharide structure shown in A, the monosaccharide units are linked as follow...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to synthetic fucosylated oligosaccharide for use in the treatment or prophylaxis of an infection with a Norwalk-like Virus or Rotavirus of a mammal, wherein the synthetic fucosylated oligosaccharide comprises a non-reducing end and an reducing end, wherein the reducing end comprises a first carbohydrate unit consisting of a galactose (Gal) linked via a ²1-4 glycosidic bond to a glucose (Glc), and wherein the non-reducing end comprises a second carbohydrate unit linked via a ²1-3 glycosidic bond to the first carbohydrate unit of the reducing end, and wherein the second carbohydrate unit comprises a) at least one or more of a fucose (Fucose) and a Galactose (Gal), and b) at least one or more of a N-acetylglucosamine (GlcNAc) or a N-acetylgalactosamine (GalNAc).

Description

technical field [0001] The present invention relates to synthetic or recombinant fucosylated oligosaccharides for use in the treatment or prevention of Norwalk-like virus or rotavirus infection in mammals. Background technique [0002] Norwalk-like viruses (NLV), also known as Noroviruses, are non-enveloped viruses belonging to the Calicivirus family. They are the most common cause of viral acute gastroenteritis in humans and affect people of all ages. The virus is transmitted by fecal-contaminated food or water, by person-to-person contact, and by aerosolization of the virus and subsequent contamination of surfaces. Norovirus infection is characterized by nausea, forceful vomiting, watery diarrhea, and abdominal pain. When severely infected, especially young children, the elderly, and people with weakened immune systems are often at risk of death. Norovirus is highly contagious, and few viral particles can already cause infection, which explains the rapid and excessive t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/715A61P31/14
CPCA61K31/702A61K31/715A61P31/14
Inventor 斯特凡·延内魏因
Owner CHR HANSEN HMO GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com